6 results about "Decidua" patented technology

The invention relates to application of arachidonic acid (ARA) in preparation of a medicine for treating sleep disorder related spontaneous abortion. Peripheral blood lipid metabolism sequencing analysis finds that the ARA content in peripheral blood serum of a patient suffering from sleep disorder and repeated pregnancy loss is most obviously reduced compared with that of a patient suffering from normal sleep and normal pregnancy; an enzyme-linked immunosorbent assay test shows that the content of ARA in decidua stromal cells (DSCs) of a patient with sleep disorder and repeated pregnancy loss is remarkably reduced compared with that of a pregnant person with normal sleep; after the endometrial stromal cells (ESCs) are subjected to ARA treatment, the in-vitro decidualization level is increased; the ARA inhibitor can be used for inhibiting the in-vitro deciduation level of the ESCs; compared with a mouse with normal sleep, the content of ARA in peripheral blood and DSCs of a mouse with sleep disorder is remarkably reduced, decidua is poor, and the abortion rate is increased; supplementing ARA can improve decidua disorder and high abortion rate caused by sleep disorder. Therefore, a potential target and a new idea are provided for diagnosis and treatment of repeated pregnancy loss related to sleep disorder.

The invention discloses a co-culture model based on endometrial stromal cell organoid and follicle organoid as well as a construction method and application of the co-culture model, and belongs to the technical field of reproductive medicine and cell engineering. The invention discloses a construction method of a co-culture model based on an endometrial stromal cell organ and a follicle organ. The construction method comprises a culture method of the follicle organ, a culture method of the endometrial stromal cell organ and co-culture of the follicle organ and the endometrial stromal cell organ. The 3D follicle-like organ and endometrial stromal cell-like organ co-culture system provided by the invention can reproduce in-vivo physiological conditions more truly, can be used for exploring a deciduous molecular mechanism, and also has the potential of constructing a high-throughput detection platform for drugs and environmental toxicants.

Provided herein are devices and methods for mimicking the anatomy and physiology of a pregnancy comprising: a body defining a central cavity, inlet and outlet apertures in fluid communication with the central cavity of the body, wherein the central cavity comprises decidual cells; a first plurality of chambers in fluid communication with the central cavity, wherein the first plurality of fetal chambers comprise cells of fetal origin; a second plurality of chambers in fluid communication with the central cavity opposite the first plurality of chambers, wherein the first plurality of fetal chambers comprise cells of maternal origin; a third chamber in fluid communication with the central cavity, wherein the first plurality of fetal chambers comprise cells of the myometrium; wherein the integration of inputs and outputs from the central chamber, the first, second, and third pluralities of chambers mimics the anatomy and physiology of a pregnancy.

This invention provides the application of lecithin in the preparation of drugs for the prevention and / or treatment of infertility, belonging to the field of biomedical preparation technology. Specifically, it relates to the application of lecithin in the preparation of drugs for the prevention and / or treatment of infertility, recurrent miscarriage, and / or uterine decidualization disorders. The lecithin can effectively reduce TNF-α levels in early pregnancy, improve uterine decidualization disorders, and increase endometrial receptivity, thereby increasing pregnancy rates and providing a new approach for the treatment of infertility and recurrent miscarriage.

This invention discloses the application of bavachin in the preparation of drugs for alleviating and / or preventing senescence of uterine decidual stromal cells, belonging to the field of biomedical technology. Through drug library screening and experimental verification, this invention found that bavachin can significantly alleviate the senescent phenotype of human uterine decidual stromal cells, reduce the expression of senescence-related markers, and alleviate decidual stromal cell senescence by regulating intracellular copper ion metabolism and transport to maintain intracellular and extracellular copper ion homeostasis. This invention provides a novel drug target and intervention strategy for clinically improving endometrial decidual function and treating related reproductive health problems. This invention also provides the application of bavachin in the preparation of drugs for alleviating senescence of uterine decidual stromal cells.

The application discloses application of Biochanin A in preparation of a medicine for inhibiting or improving uterine decidua stromal cell senescence, and belongs to the field of biomedical technology. Through drug chemical library screening and experimental verification, it is found that Biochanin A can significantly alleviate the senescence phenotype of human uterine decidua stromal cells, reduce the expression of senescence-related markers, and alleviate decidua stromal cell senescence through regulation of mitochondrial energy metabolism. The application provides a brand-new drug target and intervention strategy for improving endometrial decidua function and treating related reproductive health problems in clinic, and provides application of Biochanin A in preparation of a medicine for alleviating uterine decidua stromal cell senescence.